Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell cycle regulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Cell cycle regulation. Displaying page 1 of 1.
    EudraCT Number: 2007-005116-12 Sponsor Protocol Number: CRAD001C2428 Start Date*: 2008-03-20
    Sponsor Name:Technical University of Munich
    Full Title: Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New ...
    Medical condition: Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the furthe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000106-37 Sponsor Protocol Number: 37.07.-92906 Start Date*: 2008-08-28
    Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
    Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
    Medical condition: Psoriasis vulgaris (Plaque-Typ)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004643-80 Sponsor Protocol Number: DS1062-A-U301 Start Date*: 2021-03-10
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Completed) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002874-10 Sponsor Protocol Number: 2022-3545 Start Date*: 2022-12-16
    Sponsor Name:Gustave Roussy
    Full Title: Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma
    Medical condition: Newly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002620-17 Sponsor Protocol Number: B7461001 Start Date*: 2014-03-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.
    Medical condition: Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) or ROS oncogene 1 (ROS1)-positive (ROS1+) advanced non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000388-21 Sponsor Protocol Number: IReP Start Date*: 2020-12-23
    Sponsor Name:Ruprecht-Karls University Heidelberg, Medical Faculty, repr. by HD University Hospital and its Commercial Managing Dir.
    Full Title: Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell ...
    Medical condition: resectable Stage II, IIIA and select IIIB non-squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023022-20 Sponsor Protocol Number: CLL2S Start Date*: 2011-08-03
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agen...
    Medical condition: CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analogues
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    15.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002555-10 Sponsor Protocol Number: DS1062-A-U304 Start Date*: 2022-07-21
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cance...
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004074-25 Sponsor Protocol Number: ABc2 Start Date*: 2020-08-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer
    Medical condition: We investigated, in a population of patients with breast cancer, the combined effect of azithrocyn, docyciclin and vitamin C on biomarkers associated with cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004865 10079328 Breast tumor excision LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002909-49 Sponsor Protocol Number: ONCO 120 Start Date*: 2007-11-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: Neoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study
    Medical condition: Patients with histologically proven prostate adenocarcinoma (non metastatic)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029096 Neoplasm prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000397-30 Sponsor Protocol Number: Ponatinib-3001 Start Date*: 2018-10-23
    Sponsor Name:Millenium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda pharmaceutical Company Limited)
    Full Title: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelp...
    Medical condition: Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080018 Philadelphia positive acute lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FI (Completed) BG (Completed) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023584-17 Sponsor Protocol Number: RAS-AZIC Start Date*: 2012-08-31
    Sponsor Name:Universität Leipzig
    Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent...
    Medical condition: acute myeloid leukeamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001177-32 Sponsor Protocol Number: HEP101 Start Date*: 2016-08-09
    Sponsor Name:Promethera Biosciences
    Full Title: Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure
    Medical condition: The study will recruit cirrhotic patients who are hospitalized for Acute-on-chronic liver failure (ACLF) or Acute Decompensation at risk of developing ACLF. ACLF combines an acute deterioration of...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10008954 Chronic liver disease and cirrhosis LLT
    20.1 100000004871 10049844 Acute liver failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-000670-22 Sponsor Protocol Number: 301 Start Date*: Information not available in EudraCT
    Sponsor Name:Y-mAbs Therapeutics, Inc.
    Full Title: A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory M...
    Medical condition: Medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004567-36 Sponsor Protocol Number: MK-3475-240 Start Date*: 2016-05-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) DK (Completed) HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000140-42 Sponsor Protocol Number: 2215-CL-0301 Start Date*: 2016-04-20
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
    Medical condition: Relapsed or Refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) IE (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020337-99 Sponsor Protocol Number: WA21092 Start Date*: 2011-10-20
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) LV (Completed) HU (Completed) FI (Completed) DE (Completed) BE (Completed) SK (Completed) AT (Completed) NL (Ongoing) LT (Completed) EE (Completed) PT (Completed) BG (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002552-27 Sponsor Protocol Number: B9991004 Start Date*: 2016-07-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WI...
    Medical condition: Locally advanced or metastatic solid tumors [eg, non-small cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN)] triple-negative breast cancer (TNBC), or col...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001488-10 Sponsor Protocol Number: APHP200080 Start Date*: 2020-10-05
    Sponsor Name:Assistance Publique Hopitaux de Paris
    Full Title: Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening
    Medical condition: Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection , and for the standard of care including concurrent temoradiation and adjuvant T...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000359-15 Sponsor Protocol Number: DZB-CS-201 Start Date*: 2020-02-11
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
    Medical condition: urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 09 11:56:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA